Innovation was key to creating effective vaccines in the fight against COVID-19. Now, those innovations are being studied for the creation of leading edge influenza vaccines, explains Ethan Settembre, VP, R&D for Seqirus. He talks about how Seqirus is leveraging existing cell and adjuvant technology to deliver effective vaccines and exploring the combination of the two in aQIVc, the company’s next pipeline vaccine. Ethan also speaks to self-amplifying mRNA, the next-generation mRNA platform Seqirus is evaluating for influenza.
